Injection Site Reactions from an Integrated Analysis of Phase 2 and Phase 3 Clinical Trials of Lebrikizumab Treatment in Moderate-To-Severe Atopic Dermatitis
AuthID
P-00Y-TGA
P-00Y-TGA
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service